Personalized oxycodone dosing: Using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness

Pain Medicine (United States)

Volumn 15, Issue 5, 2014, Pages 791-806

  Linares, Oscar A ^a   Daly, David ^a   Linares, Annemarie Daly ^b   Stefanovski, Darko ^c   Boston, Raymond C ^d  

^a Plymouth Pharmacokinetic Modeling Study Group   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical pharmacokinetics; Clinical pharmacology; CYP2D6; Mathematical medicine; Metabolism; Oxycodone; Pharmacogenetics; Pharmacogenomics; Pharmacokinomics

Indexed keywords

CYTOCHROME P450 2D6; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ADULT; ANALGESIA; ARTICLE; CASE REPORT; COMPUTER MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; HEPATORENAL SYNDROME; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC PARAMETERS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; POPULATION RESEARCH; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE; ALGORITHM; BIOLOGICAL MODEL; CHRONIC PAIN; GENETICS; GENOTYPE; NONLINEAR SYSTEM; PAIN, POSTOPERATIVE; PROCEDURES; RISK;

ADULT; ALGORITHMS; ANALGESICS, OPIOID; CHRONIC PAIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; OXYCODONE; PAIN, POSTOPERATIVE; PHARMACOGENETICS; PHENOTYPE; RISK;

EID: 84901038419     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12380     Document Type: Article

References (73)

1. Katz N. The impact of pain management on quality of life. J Pain Symptom Manage 2002;24(suppl 1):S38-47.
2. Strine TW, Hootman JM, Chapman DP, Okoro CA, Balluz L. Health-related quality of life, health risk behaviors, and disability among adults with pain-related activity difficulty. Am J Public Health 2005;95(1):2042-2048.
3. Watkins E, Wollan PC, Melton IIIJ, Yawn BP. Silent pain sufferers. Mayo Clin Proc 2006;8(12):167-171.
4. Conroy DL. Out of the Nightmare: Recovery from Depression and Suicidal Pain. Lincoln, NE: Authors Choice Press; 2006.
5. Fishbain DA. Current research on chronic pain suicide. Am J Public Health 1996;86(9):1320-1321.
6. The Institute of Medicine of the National Academies Committee on Advancing Pain Research CaEBoHSP. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
7. Pizzo PA, Clark NM. Alleviating suffering 101-Pain relief in the United States. N Engl J Med 2012;366(3):197-199.
8. Linares O, Linares A. Computational opioid prescribing: A novel application of clinical pharmacokinetics. J Pain Palliat Care Pharmacother 2011;25(2):125-135.
9. Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Med 2010;2(66):1-4.
10. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991;74:53-63.
11. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363(4):301-304.
12. Greenblatt D, Koch-Weser J. Clinical pharmacokinetics (first of two parts). New Engl J Med 1975;293(14):702-705.
13. Greenblatt D, Koch-Weser J. Clinical pharmacokinetics (second of two parts). New Engl J Med 1975;293(19):964-970.
14. Gibaldi M, Levy G. Pharmacokinetics in clinical practice. 1. Concepts. J Am Med Assoc 1976;235:1864-1867.
15. Gibaldi M, Levy G. Pharmacokinetics in clinical practice. 2. Applications. J Am Med Assoc 1976;235:1987-1992.
16. Perlin E, Taylor R, Peck C. Clinical pharmacokinetics: A simplified approach, Part 1. J Natl Med Assoc 1985;77(6):475-482.
17. Perlin E, Taylor R, Peck C. Clinical pharmacokinetics: A simplified approach, Part 2. J Natl Med Assoc 1986;78(9):835-842.
18. Mehvar R. Pharmacokinetic-based design and modification of dosage regimens. Am J Pharm Educ 1998;62:189-195.
19. Brocks DR, Mehvar R. Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet 2010;49(7):421-438.
20. Linares OA. Pharmacokinetics-based opioid prescribing: Case report. Pain Pract 2010;20(3):19-21.
21. Wastney M, Patterson B, Linares O, Greif P, Boston R. Investigating Biological Systems Using Modeling: Strategies and Software. San Diego: Academic Press; 1999.
22. Yang F, Tong X, McCarver DG, Hines RN, Beard DA. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006;33(4):485-518.
23. Smith M, Watt J, Mapp G, Cranond T. Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1991;13:126-130.
24. Jannetto PJ, Bratanow NC. Pain management in the 21st century: Utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opin Drug Metab Toxicol 2012;7(6):745-752.
25. Greenblatt DJ. Elimination half-life of drugs: Value and limitations. Annu Rev Med 1985;36:421-427.
26. Greif P, Wastney M, Linares O, Boston R. Balancing needs, efficiency, and functionality in the provision of modeling software: A perspective of the NIH WinSAAM project. Adv Exp Med Biol 1998;445:3-20.
27. Lyne A, Boston R, Pettigrew K, Zech L. EMSA: A SAAM service for the estimation of population parameters based on model fits to identically replicated experiments. Comput Meth Programs Biomed 1992;38:117-151.
28. Landlaw EM, DiStefano JJ. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 1984;246:R665-677.
29. Haessel W. Measuring goodness of fit in linear and nonlinear models. South Econ J 1978;44(3):648-652.
30. 2. Am Stat 1985;39:279-285.
31. Yafune A, Ishiguro M. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. Stat Med 1999;18:581-599.
32. Yafune A, Ishiguro M. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. II: A bootstrap modification of standard two-stage (STS) method for Phase I trial. Stat Med 1999;18:601-612.
33. Saiki R, Gelfand DH, Stoffel S, etal. Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 1988;239:487-491.
34. Samer CF, Daali Y, Wagner M, etal. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010;160(4):907-918.
35. Boston R, Moate P. A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge. Am J Physiol Regul Integr Comp Physiol 2008;294:R1140-1147.
36. Boston R, Moate P. NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test. Am J Physiol Regul Integr Comp Physiol 2008;295:R395-403.
37. Linares OA, Daly D, Stefanovski D, Boston RC. A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. J Pain Palliat Care Pharmacother 2013;27(3):1-11.
38. Lugo RA. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother 2004;18(4):17-30.
39. Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992;52:487-495.
40. Poyhia R, Seppala T, Olkkola K, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992;33:617-621.
41. Ashburn MA, Ogden LL, Zhang JY, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 2003;4(6):291-297.
42. Wu G, Furlanut M. Prediction of serum vancomycin concentration using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method. J Pharm Pharmacol 1998;50:851-856.
43. Lalovic B, Kharasch E, Hofer C. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-479.
44. Lemberg KK, Heiskanen TE, Kontinen VK, Kalso EA. Pharmacology of oxycodone: Does it explain why oxycodone has become a bestselling strong opioid? Scand J Pain 2009;1:S18-23.
45. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64(6):603-611.
46. Klimas R, Witticke D, El Fallah S, Mikus G. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration. Expert Opin Drug Metab Toxicol 2013;9(5):517-528.
47. Baselt R. Disposition of Toxic Drugs and Chemicals in Man, 8th edition. Foster City, CA: Biomedical Publications; 2009.
48. Gammaitoni AR, Galer BS, Lacouture P, Domingos J, Schlagheck T. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 2003;4(1):21-30.
49. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man, 8th edition. Foster City, CA: Biomedical Publications; 2008.
50. Porhomayon J, Leissner KB, El-Solh AA, Nader ND. Strategies in postoperative analgesia in the obese obstructive sleep apnea patient. Clin J Pain 2013;29(11):998-1005.
51. Hicks JK, Crews KR, Hoffman JM, etal. A clinician-driven automated system for integration of pharmacogenetic interpretation into an electronic medical record. Clin Pharmacol Ther 2012;92(5):563-566.
52. Overby CL, Tarcczy-Hornoch P, Kalet IJ, etal. Developing a prototype system for integrating pharmacogenomics findings into clinical practice. J Pers Med 2012;2:241-256.
53. Andreassen TN, Klepstad P, Davies A, etal. Influences on the pharmacokinetics of oxycodone: A multicentre corss-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 2011;67:493-506.
54. De Gregori M, De Gregori S, Ranzani G, etal. Individualizing pain therapy with opioids: The rational approach based on pharmacogenetics and pharmacokinetics. Eur J Pain Suppl 2010;4:245-250.
55. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-173.
56. Lalovic B, Phillips B, Rissler L, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A4 to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-454.
57. Peck C. Therapeutic decision-making for second-year medical students. J Med Educ 1981;56:1024-1026.
58. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011;55(9):4006-4011.
59. Chatellier G, Colombet I, Degoulet P. An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation. Int J Med Inform 1998;49:311-320.
60. Pou L, Rosell M, Lopez R, Pascual C. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996;18:149-153.
61. Bachmann K, Belloto R Jr. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999;15(3):235-250.
62. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part I. Clin Pharmacokinet 2009;48(11):689-723.
63. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part II. Clin Pharmacokinet 2009;48(12):761-804.
64. Mercandante S, Arcuri E. Opioids and renal function. J Pain 2004;5(1):2-19.
65. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011;25:525-551.
66. Mechlin MB, Maixner W, Light KC, Fisher JM. African Americans show alterations in endogenous pain regulatory mechanisms and reduced pain tolerance to experimental pain procedures. Psychosom Med 2005;67:948-956.
67. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997;86(12):1328-1333.
68. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal 1997;9(3):237-248.
69. Kirchheiner J, Heesch C, Bauer S, etal. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76(4):302-312.
70. Bernard S, Neville KA, Nguyen AT, Flockart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006;11(2):126-135.
71. FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death. FDA Website 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm339112.htm [accessed December 2013].
72. Wagner J, Metzler C. Prediction of blood levels after multiple doses from single dose blood level data: Data generated with two-compartment open model analysed according to the one-compartment open model. J Pharm Sci 1969;58(1):87-92.
73. Dvorchik B, Vesell E. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther 1978;23(6):617-623.